bf/NASDAQ:BOLT_icon.jpeg

NASDAQ:BOLT

Bolt Biotherapeutics

  • Stock

USD

Last Close

0.77

24/05 20:00

Market Cap

40.62M

Beta: 0.99

Volume Today

557.54K

Avg: 250.78K

PE Ratio

−0.60

PFCF: −0.56

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including...Show More

Earnings

Earnings per Share (Estimate*)

-15-10-52019-12-312021-03-312021-12-312022-11-102023-08-072024-08-05

Revenue (Estimate*)

500K1M1.50M2M2.50M3M3.50M2019-12-312021-03-312021-12-312022-11-102023-08-072024-08-05

*Estimate based on analyst consensus